Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis.

Bugeja A, Harris S, McCormick B, Brown PA, Liberty C, Krepelka T, St-Cyr G, Akbari A.

Am J Nephrol. 2019;50(4):255-261. doi: 10.1159/000502506. Epub 2019 Aug 21.

PMID:
31434091
2.

Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.

Lord H, Jean N, Dumont M, Kassis J, Leblanc M.

Am J Nephrol. 2002 Jan-Feb;22(1):58-66.

PMID:
11919404
3.

Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis.

Kirwan CJ, Baig ZF, Platton S, MacCullum PK, Ashman N.

Nephron Clin Pract. 2013;123(1-2):7-12. doi: 10.1159/000351047. Epub 2013 Jun 4.

PMID:
23751953
4.

Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.

Christidou FN, Frangia TK, Bamichas GI, Gionanlis LC, Natse TA, Georgoulis IE, Sombolos KI.

Int J Clin Pharmacol Ther. 2005 Jul;43(7):335-8.

PMID:
16035376
5.

Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.

Al-Saran KA, Sabry A, Taha M, Ghafour MA, Al Fawzan F.

Saudi J Kidney Dis Transpl. 2010 Jan;21(1):43-9.

6.

Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.

Rodger MA, Ramsay T, MacKinnon M, Westphal M, Wells PS, McCormick B, Knoll G.

Am J Kidney Dis. 2012 Sep;60(3):427-34. doi: 10.1053/j.ajkd.2012.01.020. Epub 2012 Apr 4.

PMID:
22480794
7.

Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.

Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA.

Am J Kidney Dis. 2002 Sep;40(3):531-8.

PMID:
12200805
8.

Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis.

Egfjord M, Rosenlund L, Hedegaard B, Buchardt HL, Stengel C, Gardar P, Andersen L, Andersen L.

Artif Organs. 1998 Aug;22(8):633-7.

PMID:
9702313
9.

Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.

Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA.

Int J Clin Pharmacol Ther. 2008 Apr;46(4):198-203.

PMID:
18397694
10.

An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

Soroka S, Agharazii M, Donnelly S, Roy L, Muirhead N, Cournoyer S, MacKinnon M, Pannu N, Barrett B, Madore F, Tennankore K, Wilson JA, Hilton F, Sherman N, Wolter K, Orazem J, Feugère G.

Can J Kidney Health Dis. 2018 Nov 4;5:2054358118809104. doi: 10.1177/2054358118809104. eCollection 2018.

11.

Tinzaparin reduces health care resource use for anticoagulation in hemodialysis.

Pettigrew M, Soltys GI, Bell RZ, Daniel N, Davis JR, Senecal L, Leblanc M.

Hemodial Int. 2011 Apr;15(2):273-9. doi: 10.1111/j.1542-4758.2011.00531.x. Epub 2011 Feb 22.

PMID:
21338468
12.

[Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].

Barata JD, Oliveira C, Bruges M, Gusmão L, Santana A, Ponce P, Simões J, Freire I, Crespo F, da Silva AN.

Acta Med Port. 1992 Feb;5(2):65-70. Portuguese.

13.

Association between patient psychosocial characteristics and receipt of in-center nocturnal hemodialysis among prevalent dialysis patients.

Wilk AS, Tang Z, Hoge C, Plantinga LC, Lea JP.

Hemodial Int. 2019 Oct 3. doi: 10.1111/hdi.12782. [Epub ahead of print]

PMID:
31579998
14.

Lipoprotein lipase responds similarly to tinzaparin as to conventional heparin during hemodialysis.

Mahmood D, Grubbström M, Lundberg LD, Olivecrona G, Olivecrona T, Stegmayr BG.

BMC Nephrol. 2010 Dec 6;11:33. doi: 10.1186/1471-2369-11-33.

15.

Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.

Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y.

Am J Kidney Dis. 2008 May;51(5):789-95. doi: 10.1053/j.ajkd.2007.12.040.

PMID:
18436089
16.

Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis.

Wald R, Yan AT, Perl J, Jiang D, Donnelly MS, Leong-Poi H, McFarlane PA, Weinstein JJ, Goldstein MB.

BMC Nephrol. 2012 Jan 19;13:3. doi: 10.1186/1471-2369-13-3.

17.

Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.

Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G.

Kidney Blood Press Res. 2004;27(4):211-7. Epub 2004 Jul 20.

18.

Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study.

Kessler M, Gangemi C, Gutierrez Martones A, Lacombe JL, Krier-Coudert MJ, Galland R, Kielstein JT, Moureau F, Loughraieb N.

Hemodial Int. 2013 Apr;17(2):282-93. doi: 10.1111/j.1542-4758.2012.00733.x. Epub 2012 Aug 23.

PMID:
22925178
19.

[The risk of bleeding associated with low molecular weight heparin in patients with renal failure].

Lai S, Barbano B, Cianci R, Gigante A, Di Donato D, Asllanaj B, Dimko M, Mariotti A, Morabito S, Pugliese F.

G Ital Nefrol. 2010 Nov-Dec;27(6):649-54. Italian.

PMID:
21132647
20.

Nutritional status after conversion from conventional to in-centre nocturnal hemodialysis.

Noori N, Yan AT, Kiaii M, Rathe A, Goldstein MB, Bello O, Wald R.

Int Urol Nephrol. 2017 Aug;49(8):1453-1461. doi: 10.1007/s11255-017-1595-x. Epub 2017 Apr 29.

PMID:
28456922

Supplemental Content

Support Center